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ABSTRACT 
The present study was aimed towards development and evaluation of tablet as a floating-Mucoadhesive 
drug delivery system, which can provide sustained release of the model drug. The work also was aimed to study 
various parameters affecting the behavior of floating-mucoadhesive tablet in oral dosage form. Formulation of 
Gastro-Retentive Dosage Forms (GRDFs) containing suitable drug candidate which would remain in stomach and/or 
upper part of GIT for prolonged period of time thereby is maximizing the drug release at desired site within the time 
before GRDFs leave the stomach and or upper part of GIT. Dipyridamole is BCS class II drug having low solubility 
and high permeability. It is soluble at low pH but insoluble in high pH   (i.e. alkaline ph of small intestine )its oral 
bioavailability is 37-66% & biological half life is also short (40 min). In this study the bioavailability of the 
dipyridamole increase by using  various concentration of HPMC, Carbapol and Sodium bicarbonate for swelling, 
mucoadhesive and floating behavior respectively. Bioadhesive strength depends upon carbapol as concentration of 
polymer increases bioadhesive strength also increases. HPMC is water Swealable but Carbapol is hydrogel in nature 
it restricts movement of polymer and affect the swelling index. 
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INTRODUCTION 
Oral delivery of drugs is by far the most preferable route of drug delivery due to the ease of administration, 
patient compliance and flexibility in formulation. Oral sustained release drug delivery system should be primarily 
aimed at achieving more predictable and increased bioavailability of drugs. 
Floating –Mucoadhesive Drug Delivery System: 
            A gastro retentive dosage form will release the drug over an extended period in the stomach and upper 
gastrointestinal tract (GIT) thus enhancing the opportunity for absorption. Various approaches have been proposed 
to control the gastric residence of drug delivery systems in the upper part of the GIT including floating drug delivery 
systems (FDDS). High density DDS, bioadhesive systems, swelling and expanding DDS, modified shape systems 
and other delayed gastric devices. FDDS is a gastro retentive dosage form (GRDF), which can prolong the gastric 
residence time (GRT) to produce an acceptable drug bioavailability.  
             FDDS is suitable for drugs with an absorption window in the stomach or the upper small intestine, for drugs 
which act locally in the stomach and for drugs that are poorly soluble or unstable in the intestinal fluid FDDS or 
hydro dynamically balanced systems have a bulk density lower than gastric fluid and thus remain buoyant in the 
stomach without affecting the gastric emptying rate for a prolonged period of time. Based on the mechanism of 
buoyancy, two distinctly different technologies, i.e. non-effervescent and effervescent systems, have been used in 
the development of FDDS. 
             The effervescent system uses matrices prepared with swellable polymers and effervescent components e.g. 
sodium bicarbonate and citric acid or stearic acid. In non-effervescent FDDS, the drug mixes with a gel forming 
hydrocolloid, which swells in contact with gastric fluid after oral administration to maintain a relatively stable shape 
and a bulk density of less than unity within the outer gelatinous barrier. The air trapped by the swollen polymer 
confers buoyancy on these dosage forms.  
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AIM AND OBJECTIVE 
 
Need for the Study 
         Drug absorption in GI tract is highly variable procedure and prolonging gastric retention of dosage form 
extend the time for drug absorption. Floating Mucoadhesive Drug Delivery System promises to be a potential 
approach for gastric retention.  
            It has been suggested for following instances that an active material should be formulated in form of 
Floating-Mucoadhesive to enhance Bioavailability.  
1. Having improper dissolution or stability problem in small intestine. 
2. Needs local effect in stomach. 
      3.   Being absorbed only in stomach or upper part of intestine. 
Aim 
The present study was aimed towards development and evaluation of tablet as a floating-Mucoadhesive 
drug delivery system, which can provide sustained release of the model drug. The work also was aimed to study 
various parameters affecting the behavior of floating-mucoadhesive tablet in oral dosage form. Formulation of 
Gastro-Retentive Dosage Forms (GRDFs) containing suitable drug candidate which would remain in stomach and/or 
upper part of GIT for prolonged period of time thereby is maximizing the drug release at desired site within the time 
before GRDFs leave the stomach and or upper part of GIT. 
Objective   
The Major objectives of the work are: 
 To develop an optimized method for floating-Mucoadhesive matrix tablet of Dipyridamole.   
  Study the effect of various processing parameters. 
  Formulation and evaluation of floating-Mucoadhesive matrix tablet of Dipyridamole. 
 
MATERIAL AND METHOD 
The following materials that were Pharma grade or the best possible Laboratory Reagent were used as 
supplied by the manufacturer without further purification or investigation.  
 
 Materials  
Table No.1: List of chemicals used with grade and supplier 
Sr. No. Materials Used Grade Manufacturer 
1. Dipyridamol Pharma Torrent Pharma Ltd., Mumbai 
2. HPMC K4M LR Colorcon Asia Pvt.Ltd. 
3 Carbopol 934P LR Noveon Chemicals, Mumbai 
4. Sodium bicarbonate LR S.D. Fine Chem. Ltd 
5 Magnesium sterate LR S.D. Fine Chem. Ltd  
6 Lactose LR S.D. Fine Chem. Ltd. 
7 Con HCl LR Ranbaxy Fine Chemicals Ltd, New Delhi 
Preformulation Studies 
   
   Identification Tests 
a) IR Spectroscopy 
41, 42 
 The FT-IR spectrum of the obtained sample of drug was compared with the standard FT-IR spectra of the 
pure drug. 
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b) Solubility analysis: 
Preformulation solubility analysis was done to select a suitable solvent system to dissolve the drug and also 
to test its solubility in the dissolution medium which was to be used. 
c) Melting Point determination: 
Melting point determination of the obtained drug sample was done because it is a good first indication of 
purity of the sample since the presence of relatively small amount of impurity can be detected by a lowering as well 
as widening in the melting point range. 
  Compatibility Studies
 43, 44
 
a) IR Spectroscopy: 
FT-IR spectroscopy was carried out to check the compatibility between drug and polymers. The FT-IR 
spectra of drug with polymers were compared with the standard FT-IR spectrum of the pure drug.  
b) Preparation of o.1 N HCL 
8.5 ml of concentrated HCL was taken and diluted with distilled water up to 1000 ml. 
c) Preparation of Standard Calibration curve of Dipyridamole 
      10 mg Dipyridamole was accurately weighed and dissolves in small portion of 0.1N HCL in a 100 ml volumetric 
flask then volume was made up to 100 ml with 0.1N HCL. This was the primary stock solution of concentration100 
μg/ml. From this primary stock solution 20 ml was accurately taken and diluted up to 100ml, this was the second 
stock solution of concentration 20 μg/ml form second stock solution withdraw 1ml, 2ml up to 10ml & make up 10ml 
to make resulting solutions of concentration 2,4, up to 20 μg/ml respectively. The absorbance of solution were 
measured against in 0.1NHCL as a blank at 283 nm the uv spectrophotometer the plot of absorbance vs 
concentration was plotted and beers rang was determined    
Formulation and Preparation of Floating-Mucoadhesive Dipyridamole tablet by direct compression 
, 46
 
Weight all the ingredient accurately  fist add polymer hpmck4m in mortar then carbopol 934p & sodium bi 
carbonate mix it well for 10 min then add drug &lactose blend for 10 min at the last magnesium stearate 1% add mix 
all ingredient homogenously to form a tablet mix for direct compression  
Table No 2: Formulation Chart of Floating-Mucoadhesive Dipyridamole Tablets  
 
 
 
 
 
 
 
 
 
 
 
Ingeridents F1 F2 F3 F4 F5 F6 F7 F8 F9 
Diyridamole (mg) 150 150 150 150 150 150 150 150 150 
Hpmc k4m (mg) 60 60 60 70 70 70 80 80 80 
Carbopol 934 (mg) 15 20 25 15 20 25 15 20 25 
NaHco3 (mg) 30 30 30 30 30 30 30 30 30 
Mg. St.(mg) 3 3 3 3 3 3 3 3 3 
Lactose (mg) 42 37 32 32 27 22 22 17 12 
TOTAL WT (mg) 300 300 300 300 300 300 300 300 300 
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RESULT & DISSCUSSION 
 
Preparation of standard calibration curve of Dipyridamole in 0.1 N HCL (λ max 283 nm) 
 
Graph No 1: Standard calibration curve of Dipyridamole at 283nm. 
The linear regression analysis was done on Absorbance data points. The results are as follows- 
For standard curve in 0.1N HCL 
 The slope         =  0.050 
The intercept       =  0.017 
The correlation  coefficient  ( R2 ) =  0.997 
 
Compatibility study by IR spectroscopy 
 
Graph No 2:-IR spectra of pure drug: (Dipyridamole) 
   
 
 
The FT-IR spectrum of the Dipyridamole pure drug was found to be similar to the standard spectrum of 
Dipyridamole. The spectrum of Dipyridamole showed the following functional groups at their frequencies. 
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                                           Table no 4:     IR spectra of pure drug 
Group Wave Number 
O-H stretch 
C-C stretch 
N-H stretch 
N-H bending 
C-C stretch 
3381.21 
2920.23 
3050 
1569.73 
759.95 
 
 
Graph No 3:-IR Spectra of combination of Dipyridamole+all excipients 
Table No. 5: Comparison of the peak of functional groups observed in IR spectra of compatibility studies 
Functional group O-H stretch C-H stretch(in 
cH2) 
N-H stretch N-H Bending C-C Stretch 
Dipyridamole 3381.21 2920.23 3050 1569.73 759.95 
Dipyridamole+all 
excipients 
3381.21 2920.23 30050 1569.73 759.95 
                              
 
Determination of Maximum Absorption Wavelength (λ max)  
The ultraviolet spectrum of Dipyridamole is obtained by scanning from 200 to 400 nm at a medium scan 
rate. The resulting spectrum is qualitatively compared to the spectrum obtained from a Dipyridamole reference 
standard. The drug substance spectrum is characterized by maxima at 283 nm. 
 
Graph No 4: Maximum Absorption Wavelength (λ max ) 
Solubility Analysis 
 Obtained sample was found to be freely soluble in 0.1 n HCL & ethanol practically insoluble in water. . It 
complies with USP standards44 thus indicating the purity of the drug sample. 
Melting point determination:  
The melting point of the obtained drug sample was found to be 163oC which is the reported range of 163-
169oC. It complies with USP standards44 thus indicating the purity of the drug sample 
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Evaluation physical property of powder  
Table No. 6: Flow Properties of Dipyridamol Powder 
Batch Angle of Repose 
() 
Bulk Density 
(g/cm
3
) 
Tapped Density 
(g/cm
3
) 
Compressibility Index Hausner 
Ratio 
F1 26.3455± 1.65 0.5 0.562 11.481±1.18 1.129±0.46 
F2 28.0529±1.23 0.5 0.569 12.22±1.26 1.139±0.16 
F3 28.4535 ±1.49 0.5 0.575 13.33±0.89 1.153±0.68 
F4 29.6894±2.16 0.5 0.580 13.88±0.82 1.611. ±0.89 
F5 30.9689±2.41 0.5 0.588 15±0.59 1.176±0.56 
F6 30.3222±1.89 0.5 0.596 16.11±0.69 1.192±.0.78 
F7 31.3031±1.28 0.5 0.604 16.66±0.78   1.2±0.86 
F8 32.1329±  1.64 0.5 0.620 19.44±0.84 1.241±0.51 
F9 32.7568 ±1.74 0.5 0.629 20.55±0.78 1.258±0.43 
Evaluation of physical properties of tablets 
Table No. 7: Evaluation parameters of Tablet formulations 
Formulation 
code 
Evaluation parameters 
Thickness ± S.D. (mm) 
(n = 3) 
Hardness ± S.D. 
(kg/cm
2
) (n = 3) 
Friability             
(%) 
Average weight 
(variation in mg) 
F1 4.554±0.057 3.4±0.12 0.167 301.8±3.12 
F2 4.451±0.052 4±0.17 0.213 301.55±2.41 
F3 4.461±0.064 3.4±0.16 0.189 301±2.59 
F4 4.561±0.053 4.1±0.18 0.198 299.75±2.34 
F5 4.567±0.061 4.1±0.12 0.241 299.7±3.49 
F6 4.545±0.065 3.4±0.13 0.166 300.4±3.32 
F7 4.567±0.067 3.4±0.14 0.184 299.67±2.67 
F8 4.564±0.054 4.1±0.15 0.227 298.78±2.78 
F9 4.565±0.058 4.10.16 0.179 299.87±3.14 
 
Floating property 
 
Figure No. 1:   Dipyridamole floating tablet buoyancy time study  
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Table No. 8: Results of floating Lag time of Tablet formulations 
Formulation 
Code 
Floating 
lag time( sec) 
Total 
floating time 
(hr) 
F1 5±2 >12 
F2 10±1 >12 
F3 14±2 >12 
F4 11±1 >12 
F5 16±3 >12 
F6 20±2 >12 
F7 13±1 >12 
F8 23±3 >12 
F9 26±1 >12 
Floating time was observed in all 9 formulations, all the 9 formulations shows the floating time more than 
>12 hours which is sufficient to achieve sustained release action.  It is observe that as polymer conc. increase 
floating lack time increase  
 
Swelling study 
 
 
Graph No 5:  swelling index V/S Time for formulation f1to f9 
As the conc. of polymer higher swelling index decease this is fact as con increase restrict the movement of  
polymer  hpmck4m & carbopol have higher cross linking this indicates that polymers having cross linking constrain 
and therefore the polymer did not open up easily 
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Dissolution Study   
Graph No. 6: %cumulative drug release 
 
 
Mucoadhesive strength  
Table No. 12: Mucoadhesive strength of tablet 
Formulation Code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Strength in gm 10.14 
±0.6 
13.28 
±0.5 
17.48 
±0.3 
12.41 
±0.1 
15.12 
±0.7 
18.71 
±0.8 
16.84 
±0.32 
20.14 
±0.2 
22.58 
±0.6 
Mucoadhesive force 
in dyne 
0.99 1.30 1.71 1.21 1.48 1.83 1.65 1.97 2.21 
 
Stability study  
Table No. 13:  Stability study for optimized formulations 
Sr No. Evaluation parameter Before 
 stability 
After stability of 
30 days  
1 Hardness (kg/cm
2
) 3.4±0.13 3.4±0.13 
2 Content uniformity 98.94 98.12 
3 % CDR 99.92 98.76 
4 Mucoadhesive strength (gm) 18.71±0.8 17.64±0.2 
5 % Friability  0.166 0.172 
6 Floating lag time 20±2 17 ±2 
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Table No. 14: Release rate profile of formulation F6 after stability   
 
 
 
        Graph No 7:    Comparitive graph for In-vitro cumulative % drug released v/s time for optimized formulation-
F6 before and after stability testing 
 
CONCLUSION 
Literature survey on bioadhesive-floating drug delivery was carried out.  Dipyridamole is BCS class II drug 
having low solubility and high permeability. It is soluble at low pH but insoluble in high pH   (i.e. alkaline ph of 
small intestine )its oral bioavailability is 37-66% & biological half life is also short (40 min).all the above reason are 
suitable for gastroretentive drug delivery system .  
 After procurement of drug sample it was characterized for identification by FT-IR. After identification 
check compatibility of drug with all excipeint. It was found that it is compatible with all excipeint there is no change 
in functional group. 
 Flow property of dipyridamole tablet powder was found within range & or comply with official 
pharmacopeia. Physical property of dipyridamole tablet Hardness, friability Average weight also complies with 
standard reference. 
 Floating lag time of all nine formulation show within 1 min total floating time was more than 12 hrs. 
Hardness of tablet affect the floating lag time.  
 The in vitro release profile indicated that Batch (F6) was the most promising formulation as the extent of 
drug release from this formulation was high as compare to other formulations, which are suitable for sustained 
release drug delivery system. The in vitro drug release studies in Stomach pH conditions was carried out in pH 1.2 
buffer for 12 hrs. The Batch F6 shows 99.92% release in 12 hrs, so we concluded that rate of drug release increases 
in the Acidic environment of Stomach. Formulation f6 show desirable swelling index and bioadhesive property. 
Bioadhesive strength depends upon carbapol as concentration of polymer increases bioadhesive strength also 
increases. HPMC is water Swealable but Carbapol is hydrogel in nature it restricts movement of polymer and affect 
the swelling index. 
 Release kinetic data of all the formulation showed that F1-F9 formulation follows korsmeyer-peppas 
model. 
 Stability study was conducted on tablets of Batch F6 at 40±20C for one months. Tablets were evaluated for 
drug release pattern, hardness, floating behavior and in vitro bioadhesion. No significant changes were observed in 
any of the studied parameters during the study period, thus it could be concluded that formulation was stable. 
 From the discussion it was concluded that the tablets of Batch F6 had considerable bioadhesion along with 
considerable floating and swelling behaviors with good drug release pattern. Tablets of Batch F6was selected as an 
optimum batch and evaluated for stability study.  
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 From the discussion it was concluded that the tablets of Batch F6had considerable bioadhesion along with 
considerable floating and swelling behaviors with good drug release pattern. Tablets of Batch F6 was selected as an 
optimum batch and evaluated for stability study. 
 The stability study revealed that there was no significant change in the dissolution profile and bioadhesive 
strength for a period of 1 month. 
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